Vanguard Group Inc Inhibikase Therapeutics, Inc. Transaction History

Vanguard Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.45 - $5.41 $80 - $962	178 Added 0.03%	530,276 $265,000
Q1 2022 May 13, 2022	BUY	$1.03 - $1.77 $52,935 - $90,967	51,394 Added 10.74%	530,098 $785,000
Q3 2021 Nov 12, 2021	BUY	$1.79 - $2.81 $14,479 - $22,730	8,089 Added 1.72%	478,704 $909,000
Q2 2021 Aug 13, 2021	BUY	$2.8 - $6.23 $1.32 Million - $2.93 Million	470,615 New	470,615 $1.32 Million

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $80.7M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.